MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study.
The uncertainties inherent in clinical measures of prostate cancer (CaP) aggressiveness endorse the investigation of clinically validated tissue biomarkers. MUC1 expression has been previously reported to independently predict aggressive localized prostate cancer. We used a large cohort to validate...
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5112958?pdf=render |
id |
doaj-c8acb3ceaf684fd1a6ee51deabd183eb |
---|---|
record_format |
Article |
spelling |
doaj-c8acb3ceaf684fd1a6ee51deabd183eb2020-11-25T01:46:08ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-011111e016523610.1371/journal.pone.0165236MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study.Okyaz EminagaWei WeiSarah J HawleyHeidi AumanLisa F NewcombJeff SimkoAntonio Hurtado-CollDean A TroyerPeter R CarrollMartin E GleaveDaniel W LinPeter S NelsonIan M ThompsonLawrence D TrueJesse K McKenneyZiding FengLadan FazliJames D BrooksThe uncertainties inherent in clinical measures of prostate cancer (CaP) aggressiveness endorse the investigation of clinically validated tissue biomarkers. MUC1 expression has been previously reported to independently predict aggressive localized prostate cancer. We used a large cohort to validate whether MUC1 protein levels measured by immunohistochemistry (IHC) predict aggressive cancer, recurrence and survival outcomes after radical prostatectomy independent of clinical and pathological parameters.MUC1 IHC was performed on a multi-institutional tissue microarray (TMA) resource including 1,326 men with a median follow-up of 5 years. Associations with clinical and pathological parameters were tested by the Chi-square test and the Wilcoxon rank sum test. Relationships with outcome were assessed with univariable and multivariable Cox proportional hazard models and the Log-rank test.The presence of MUC1 expression was significantly associated with extracapsular extension and higher Gleason score, but not with seminal vesicle invasion, age, positive surgical margins or pre-operative serum PSA levels. In univariable analyses, positive MUC1 staining was significantly associated with a worse recurrence free survival (RFS) (HR: 1.24, CI 1.03-1.49, P = 0.02), although not with disease specific survival (DSS, P>0.5). On multivariable analyses, the presence of positive surgical margins, extracapsular extension, seminal vesicle invasion, as well as higher pre-operative PSA and increasing Gleason score were independently associated with RFS, while MUC1 expression was not. Positive MUC1 expression was not independently associated with disease specific survival (DSS), but was weakly associated with overall survival (OS).In our large, rigorously designed validation cohort, MUC1 protein expression was associated with adverse pathological features, although it was not an independent predictor of outcome after radical prostatectomy.http://europepmc.org/articles/PMC5112958?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Okyaz Eminaga Wei Wei Sarah J Hawley Heidi Auman Lisa F Newcomb Jeff Simko Antonio Hurtado-Coll Dean A Troyer Peter R Carroll Martin E Gleave Daniel W Lin Peter S Nelson Ian M Thompson Lawrence D True Jesse K McKenney Ziding Feng Ladan Fazli James D Brooks |
spellingShingle |
Okyaz Eminaga Wei Wei Sarah J Hawley Heidi Auman Lisa F Newcomb Jeff Simko Antonio Hurtado-Coll Dean A Troyer Peter R Carroll Martin E Gleave Daniel W Lin Peter S Nelson Ian M Thompson Lawrence D True Jesse K McKenney Ziding Feng Ladan Fazli James D Brooks MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study. PLoS ONE |
author_facet |
Okyaz Eminaga Wei Wei Sarah J Hawley Heidi Auman Lisa F Newcomb Jeff Simko Antonio Hurtado-Coll Dean A Troyer Peter R Carroll Martin E Gleave Daniel W Lin Peter S Nelson Ian M Thompson Lawrence D True Jesse K McKenney Ziding Feng Ladan Fazli James D Brooks |
author_sort |
Okyaz Eminaga |
title |
MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study. |
title_short |
MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study. |
title_full |
MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study. |
title_fullStr |
MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study. |
title_full_unstemmed |
MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study. |
title_sort |
muc1 expression by immunohistochemistry is associated with adverse pathologic features in prostate cancer: a multi-institutional study. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2016-01-01 |
description |
The uncertainties inherent in clinical measures of prostate cancer (CaP) aggressiveness endorse the investigation of clinically validated tissue biomarkers. MUC1 expression has been previously reported to independently predict aggressive localized prostate cancer. We used a large cohort to validate whether MUC1 protein levels measured by immunohistochemistry (IHC) predict aggressive cancer, recurrence and survival outcomes after radical prostatectomy independent of clinical and pathological parameters.MUC1 IHC was performed on a multi-institutional tissue microarray (TMA) resource including 1,326 men with a median follow-up of 5 years. Associations with clinical and pathological parameters were tested by the Chi-square test and the Wilcoxon rank sum test. Relationships with outcome were assessed with univariable and multivariable Cox proportional hazard models and the Log-rank test.The presence of MUC1 expression was significantly associated with extracapsular extension and higher Gleason score, but not with seminal vesicle invasion, age, positive surgical margins or pre-operative serum PSA levels. In univariable analyses, positive MUC1 staining was significantly associated with a worse recurrence free survival (RFS) (HR: 1.24, CI 1.03-1.49, P = 0.02), although not with disease specific survival (DSS, P>0.5). On multivariable analyses, the presence of positive surgical margins, extracapsular extension, seminal vesicle invasion, as well as higher pre-operative PSA and increasing Gleason score were independently associated with RFS, while MUC1 expression was not. Positive MUC1 expression was not independently associated with disease specific survival (DSS), but was weakly associated with overall survival (OS).In our large, rigorously designed validation cohort, MUC1 protein expression was associated with adverse pathological features, although it was not an independent predictor of outcome after radical prostatectomy. |
url |
http://europepmc.org/articles/PMC5112958?pdf=render |
work_keys_str_mv |
AT okyazeminaga muc1expressionbyimmunohistochemistryisassociatedwithadversepathologicfeaturesinprostatecanceramultiinstitutionalstudy AT weiwei muc1expressionbyimmunohistochemistryisassociatedwithadversepathologicfeaturesinprostatecanceramultiinstitutionalstudy AT sarahjhawley muc1expressionbyimmunohistochemistryisassociatedwithadversepathologicfeaturesinprostatecanceramultiinstitutionalstudy AT heidiauman muc1expressionbyimmunohistochemistryisassociatedwithadversepathologicfeaturesinprostatecanceramultiinstitutionalstudy AT lisafnewcomb muc1expressionbyimmunohistochemistryisassociatedwithadversepathologicfeaturesinprostatecanceramultiinstitutionalstudy AT jeffsimko muc1expressionbyimmunohistochemistryisassociatedwithadversepathologicfeaturesinprostatecanceramultiinstitutionalstudy AT antoniohurtadocoll muc1expressionbyimmunohistochemistryisassociatedwithadversepathologicfeaturesinprostatecanceramultiinstitutionalstudy AT deanatroyer muc1expressionbyimmunohistochemistryisassociatedwithadversepathologicfeaturesinprostatecanceramultiinstitutionalstudy AT peterrcarroll muc1expressionbyimmunohistochemistryisassociatedwithadversepathologicfeaturesinprostatecanceramultiinstitutionalstudy AT martinegleave muc1expressionbyimmunohistochemistryisassociatedwithadversepathologicfeaturesinprostatecanceramultiinstitutionalstudy AT danielwlin muc1expressionbyimmunohistochemistryisassociatedwithadversepathologicfeaturesinprostatecanceramultiinstitutionalstudy AT petersnelson muc1expressionbyimmunohistochemistryisassociatedwithadversepathologicfeaturesinprostatecanceramultiinstitutionalstudy AT ianmthompson muc1expressionbyimmunohistochemistryisassociatedwithadversepathologicfeaturesinprostatecanceramultiinstitutionalstudy AT lawrencedtrue muc1expressionbyimmunohistochemistryisassociatedwithadversepathologicfeaturesinprostatecanceramultiinstitutionalstudy AT jessekmckenney muc1expressionbyimmunohistochemistryisassociatedwithadversepathologicfeaturesinprostatecanceramultiinstitutionalstudy AT zidingfeng muc1expressionbyimmunohistochemistryisassociatedwithadversepathologicfeaturesinprostatecanceramultiinstitutionalstudy AT ladanfazli muc1expressionbyimmunohistochemistryisassociatedwithadversepathologicfeaturesinprostatecanceramultiinstitutionalstudy AT jamesdbrooks muc1expressionbyimmunohistochemistryisassociatedwithadversepathologicfeaturesinprostatecanceramultiinstitutionalstudy |
_version_ |
1725020716653346816 |